Header Graphic
Helpful Web sites

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Immunodeficiency (PI)
Idiopathic Thrombocytopenic Purpura (ITP)
General

Please note: The GAMUNEX.com Web site is intended for US residents; however, we have included some links to patient and family resources, available in English, which originate outside the US, as they have generously been made available online as a global resource for everyone affected by immune deficiency diseases.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

GBS/CIDP Foundation International

Providing support and assistance to GBS/CIDP patients and their families and committed to increasing knowledge and awareness in both the public and professional communities, the Foundation provides print information and educational opportunities, sponsors worldwide meetings, lectures and support groups, hosts the biannual GBS/CIDP International Symposium, and encourages new findings by awarding research grants for further study and experimentation.

MedlinePlus

MedlinePlus will direct you to information to help answer health questions. MedlinePlus brings together authoritative information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations. Preformulated Medline searches are included in MedlinePlus and give easy access to medical journal articles. MedlinePlus also has extensive information about drugs, an illustrated medical encyclopedia, interactive patient tutorials, and the latest health news.

National Institute of Neurological Disorders and Stroke

The mission of NINDS is to reduce the burden of neurological disease–a burden borne by every age group, by every segment of society, and by people all over the world. NINDS is the leading supporter of biomedical research on disorders of the brain and nervous system.

The Neuropathy Association

The mission of The Neuropathy Association is to help and heal people with peripheral neuropathy by providing neuropathy awareness, education, support, advocacy, and research.

Primary Immunodeficiency (PI)

Immune Deficiency Foundation (IDF)

A national voluntary health organization, the IDF is a nonprofit organization dedicated to improving the diagnosis and treatment of PI through research and education. The goal of IDF is to help patients with PI and their families to live a healthy and productive life. It also strives for a broader understanding of PI through education and outreach efforts to patients and the medical community.

Worth taking a look at:
IDF produces a variety of educational materials for patients and healthcare professionals. All publications are free of charge and can be printed from their Web site. IDF also sponsors local events such as patient meetings.

Check out the Patient and Family Handbook, a comprehensive resource for PI patients and their families.

The Jeffrey Modell Foundation, National Resource Center for Primary Immune Deficiency

The Jeffrey Modell Foundation is a nonprofit research foundation dedicated to the early and precise diagnosis, meaningful treatment, and ultimate cure of primary immunodeficiencies.

Worth taking a look at:
The site offers access to consumer publications, community and individual support through K.I.D.s (Kids with Immune Deficiencies) Days for patients and families, educational workshops, and more.

Michigan Immunodeficiency Foundation

This organization seeks to improve the quality of life of Michigan residents who suffer from primary immune deficiency diseases by increasing patient and physician education and awareness, raising and providing funds for research, and assisting patients and family members dealing with primary immunodeficiency.

International Patient Organization for Primary Immunodeficiencies (IPOPI)

IPOPI is an international organization whose members are national patient organizations for PI. It unites the experiences, expertise, resources, and influence of its members to support the commitment for worldwide improvement in the care and treatment of patients with PI.

Worth taking a look at:
Check out the FORUM section of the Web site. The postings are recent and come straight from patients and families. It's a good place to find support and make connections.

National Institute of Allergy and Infectious Diseases (NIAID)

Primary immune deficiency diseases page–fact sheets, brochures, and news releases related to PI. The Primary Immune Deficiency Fact Sheet contains information related to primary immune deficiencies, immune defects, and related blood disorders.

Idiopathic Thrombocytopenic Purpura (ITP)

In-depth look at ITP—eMedicine

An in-depth look at ITP by Michael A. Silverman, MD, Instructor, Department of Emergency Medicine, Johns Hopkins Bayview Medical Center, Saint Agnes Healthcare.

Worth taking a look at:
Statistics provided on the frequency of ITP, the mortality/morbidity associated with the disease, and sex and age of patients.

ITP Support Association

ITP patient and family education and support resource.

Platelet Disorder Support Association

Patient support Web site with information about ITP and other platelet disorders.

General

Severe Combined Immune Deficiency (SCID) Web site

Barb Ballard, parent of a child diagnosed with SCID, started this Web site as a self-help support tool and resource guide for patients and families afflicted with SCID. The majority of the information links to information outside of the Web site.

Important Safety Information for GAMUNEX

Gamunex, Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified, is indicated for the treatment of primary humoral immunodeficiency disease (PI), idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).

Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis and death. Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number. Gamunex does not contain sucrose. Glycine, a natural amino acid, is used as a stabilizer.

Gamunex is contraindicated in individuals with acute severe hypersensitivity reactions to Immune Globulin (Human). It is contraindicated in IgA deficient patients with antibodies against IgA and history of hypersensitivity.

There have been reports of noncardiogenic pulmonary edema [Transfusion-Related Lung Injury (TRALI)], hemolytic anemia, and aseptic meningitis in patients administered with IGIV.

Thrombotic events have been reported in association with IGIV. Patients at risk for thrombotic events may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity. Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IGIV therapy.

Gamunex is made from human plasma. Because this product is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

In clinical studies, the most common adverse reactions with Gamunex were headache, fever, chills, hypertension, rash, nausea, and asthenia (in CIDP); headache, cough, injection site reaction, nausea, pharyngitis, and urticaria (in PI); and headache, vomiting, fever, nausea, back pain, and rash (in ITP). The most serious adverse reactions were pulmonary embolism (PE) in one subject with a history of PE (in CIDP), an exacerbation of autoimmune pure red cell aplasia in one subject (in PI), and myocarditis in one subject that occurred 50 days post-study drug infusion and was not considered drug related (in ITP).

Please see accompanying GAMUNEX full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.